| Title |
Review of depot aripiprazole for schizophrenia
|
|---|---|
| Published in |
Patient preference and adherence, November 2013
|
| DOI | 10.2147/ppa.s32972 |
| Pubmed ID | |
| Authors |
Farha Bilal Motiwala, Kim Stasia Siscoe, Rif S El-Mallakh |
| Abstract |
Improving outcomes in schizophrenia generally requires an improvement in medication adherence. One of the most effective interventions to improve adherence is the use of depot formulations of antipsychotic medications. A new depot aripiprazole formulation for the treatment of schizophrenia will be available soon. A review of all publically available information on depot aripiprazole as of November 2012 was performed. One peer-reviewed study on depot aripiprazole is published, and the remainder of the data were presented at international scientific meetings. Depot aripiprazole appears to be both safe and effective in the long-term treatment of schizophrenia. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 36 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 17% |
| Other | 6 | 17% |
| Researcher | 6 | 17% |
| Student > Ph. D. Student | 3 | 8% |
| Professor | 2 | 6% |
| Other | 4 | 11% |
| Unknown | 9 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 33% |
| Biochemistry, Genetics and Molecular Biology | 3 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Computer Science | 2 | 6% |
| Chemistry | 2 | 6% |
| Other | 3 | 8% |
| Unknown | 12 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 November 2013.
All research outputs
#19,945,185
of 25,374,917 outputs
Outputs from Patient preference and adherence
#1,293
of 1,757 outputs
Outputs of similar age
#163,150
of 226,637 outputs
Outputs of similar age from Patient preference and adherence
#16
of 30 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,757 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.5. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,637 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.